At the heart of our corporate responsibility efforts are our two signature global health programs—the Lilly MDR-TB Partnership, which is focused on multidrug-resistant TB, and the Lilly NCD Partnership, which is focused on non-communicable diseases, specifically, diabetes. Both programs are exploring new ways to improve health outcomes for people living in communities where resources and quality healthcare are scarce.
As part of these two programs, we are using a novel approach that will amplify their reach and impact:
Through this unique approach, we focus on sharing our results with the wider health community, both globally and in our focus countries, so better decisions can be made about how to invest limited resources. Ultimately, we will advocate for the replication of the best solutions with governments and other key stakeholders to encourage their adoption on a regional, national and global scale.
For more information on Lilly’s global health programs, visit lillyglobalhealth.com